Pexidartinib and Sodium picosulfate, magnesium, and citric acid
Determining the interaction of Pexidartinib and Sodium picosulfate, magnesium, and citric acid and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist. Concomitant use of pexidartinib with proton pump inhibitors should be avoided. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: citric acid / magnesium oxide / sodium picosulfate
Brand name: Clenpiq, Prepopik
Synonyms: Citric acid, magnesium oxide, and sodium picosulfate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pexidartinib-Sodium polystyrene sulfonate
- Pexidartinib-Sodium Polystyrene Sulfonate Oral Powder
- Pexidartinib-Sodium Polystyrene Sulfonate Powder
- Pexidartinib-Sodium polystyrene sulfonate Rectal
- Pexidartinib-Sodium Polystyrene Sulfonate Suspension
- Pexidartinib-Sodium Sulf/Potassium Sulf/Mag Sulf/Polyethylene Glycol-Electrolyte Soln
- Sodium picosulfate, magnesium, and citric acid-Pexidartinib Hydrochloride
- Sodium picosulfate, magnesium, and citric acid-Pfizerpen
- Sodium picosulfate, magnesium, and citric acid-Pharaon Tea
- Sodium picosulfate, magnesium, and citric acid-Pharmorubicin Pfs
- Sodium picosulfate, magnesium, and citric acid-Phazyme
- Sodium picosulfate, magnesium, and citric acid-Phazyme Liquid Gas Relief, Maximum Strength